I-Mab Biopharma
I-Mab is a dynamic, global biotech company exclusively focused on discovery, development and soon commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases.
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
* | CNY500m | Post IPO Equity | |
| Total Funding | 000k | ||
Tasly Pharmaceutical(exited)
Cambridge Capital(exited)
Tally Capital(exited)
Hony Capital(exited)
Hillhouse Capital(exited)
EDBI(exited)
CDH Investments(exited)
C-Bridge Capital(exited)
Ally Bridge Group(exited)
HOPU Fund(exited)
Genexine(exited)
GIC(exited)
Invus(exited)
Lake Bleu Capital(exited)
Octagon Capital Partners(exited)
OrbiMed(exited)
Perceptive Advisors(exited)
Sphera Global Healthcare Fund(exited)
VMS Asset Management(exited)
CBC Group(exited)
| CNY | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (94 %) | (352 %) | (102 %) | - | - | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (2652 %) | 1088 % | (4340 %) | - | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (2649 %) | 1089 % | (5302 %) | - | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 1378 % | (408 %) | 2932 % | - | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
